-
Mashup Score: 1Sparsentan in IgA Nephropathy : The PROTECT trial — NephJC - 5 day(s) ago
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 27PubMed - 5 day(s) ago
PubMed® comprises more than 36 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full text content from PubMed Central and publisher web sites.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 12Freely Filtered 048: Putting TESTING to the Test — NephJC - 10 day(s) ago
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with st
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 5Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States - 10 day(s) ago
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A neph…
Source: www.tandfonline.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 19Nefecon in IgA Nephropathy, the Nefigard trial — NephJC - 10 day(s) ago
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 11Healing, Hype, or Harm: The NefIgArd trial — NephJC - 10 day(s) ago
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 19Nefecon in IgA Nephropathy, the Nefigard trial — NephJC - 10 day(s) ago
This week, we will discuss NEFIGARD, the trial of a targeted release steroid. It reduces proteinuria in IgA nephropathy – should it upstage humble prednisone?
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 5
Calliditas Therapeutics.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 12Freely Filtered 048: Putting TESTING to the Test — NephJC - 10 day(s) ago
Episode 048: TESTING is the latest IgA nephropathy trial and it is the comeback kid of nephrology trials. From a trial that was halted because of excess adverse events to a safe and effective therapy with just a few tweeks. Amazing turn around. Join the Filtrate as we put TESTING to the test with st
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 5Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States - 10 day(s) ago
To estimate the cost-effectiveness of Nefecon in addition to the best supportive care (BSC) vs BSC in a hypothetical cohort of commercially insured adult patients with primary immunoglobulin A neph…
Source: www.tandfonline.comCategories: General Medicine News, NephrologyTweet
Did you spare any thoughts on sparsentan? Can it PROTECT the precious kidneys from IgAN fire? We saw hope in #NephJC discussed interim analysis, but did the results followed the same positive slope in final analysis? https://t.co/KQheu4qrtB